Vela Foundation

Vela is a clinical-stage biotechnology company focused on developing transformative medicines for severe orphan diseases of the central nervous system (CNS). The company's lead program, VTX-101, is a small molecule currently in Phase 2 clinical trials for the treatment of Dravet Syndrome, a rare and severe form of epilepsy. Vela's pipeline also includes programs targeting Fragile X Syndrome and Autism Spectrum Disorder, leveraging deep expertise in neurobiology and ion channel pharmacology. By focusing on genetically defined patient populations, the company aims to address significant unmet medical needs in neurodevelopmental and neuropsychiatric conditions.